Somnomed Limited · ASX:SOM
Somnomed — Shareholder Meeting (November 2022)
22 slides from Somnomed's shareholder meeting presentation, Nov 25, 2022
Slide 1: AGM Presentation
AGM Presentation 25 November 2022 Treatment focused. Technology driven.
Slide 2: Disclaimer
Disclaimer This document has been prepared as a summary only and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This document should be read in co
Slide 3: SomnoMed's vision and mission
SomnoMed’s vision and mission Our vision is to lead in the treatment of patients suffering from obstructive sleep apnea and relevant adjacent conditions Our mission is to advance the adoption, acceptance and treatment of oral sleep apnea therapies by medical specialists, dentists, patients and insur
Slide 4: Highly qualified and supportive board of directors
Highly qualified and supportive board of directors Guy Russo Michael Gordon Karen Borg Chairman Amrita Blickstead Non-Executive Non-Executive Non-Executive Highly accomplished business Currently CFO of Currently CEO of Catholic leader with strong commercial & Former COO & CMO for eBay Different Tech
Slide 5: Experienced management team
Experienced management team Hervé Fiévet Neil Verdal-Austin Mark Harding CFO CEO VP, Global Marketing Joined SomnoMed in April 2019 28+ years experience with Joined SomnoMed in July 2019 Extensive experience in managing various medical distribution and Strong track record of executing all aspects of
Slide 6: FY22 financial highlights
FY22 financial highlights Total revenue EBITDA2 Cash A$72.6m A$1.3m A$15.6m +16% vs FY21 Stable product gross Secured net $11m Exceeded FY22 guidance margin of 70% in new debt funding North America EBITDA2 above guidance post FY22 +33% vs FY21 despite investment for Positive net Europe1 growth +15%
Slide 7: SomnoMed's market opportunity
SomnoMed’s market opportunity
Slide 8: Significant addressable markets globally
Significant addressable markets globally Obstructive sleep apnea, a growing burden on the medical system affecting a significant portion of the population Obstructive sleep apnea (OSA) is a disorder that occurs when a person’s breathing is interrupted during sleep because the airway becomes blocked
Slide 9: Improving treatment options for OSA patients
Improving treatment options for OSA patients Increasing long term cost in treatment $ $$$ COAT™ CPAP Surgery Continuous Open Airway Therapy (COAT™) works Continuous Positive by comfortably moving Airway Pressure applies Invasive option the mandible forward, air pressure to the considered opening the
Slide 10: Improving treatment effectiveness for OSA patients
Improving treatment effectiveness for OSA patients Efficacy Many patients Clinical Insight don’t get effective The findings are sobering. Our CPAP: treatment all data suggest that despite Lower Compliance night, every night numerous changes to machine x Greater Efficacy and mask dynamics as well as
Slide 11: Positioned for future growth
Positioned for future growth Technology driven Investment in the technology pathway to unlock true COAT™ potential Best in class service and technical support Growing and extensive sales and distribution footprint in both dental and medical channels Treatment focused Design and innovation driving pa
Slide 12: Rest Assure
Rest Assure ® SomnoMed’s technology-enabled oral appliance
Slide 13: Barriers to prescribing COAT: clinical evidence and reimbursement
We listened to Sleep Physician feedback Addressing device night-time CPAP patient apps provide: monitoring provides data to address • Overnight monitoring of effectiveness and compliance other barriers to prescription: • Ongoing clinical evidence and scientific publications Data from night time moni
Slide 14: Rest Assure will provide data to remove prescription barriers
® Rest Assure will provide data to remove prescription barriers ® • Rest Assure technology will determine in-mouth efficacy and compliance for COAT™ • SOM, patients, sleep physicians and sleep dentists will have access to each night’s data 7-10 minutes after patient wakes up* • Data will provide Sle
Slide 15: Rest Assure technology – how does it work?
® Rest Assure technology – how does it work? Smart oral appliance and cloud based infrastructure SOM algorithms determine AHI1, graphs, tables Patient app Smart oral appliance with sensors recording overnight data. Physician portal Patient docks their device after Raw data transferred via night’s sl
Slide 16: Rest Assure: Enabling sensor technology for COAT
Rest Assure® Enabling sensor technology for COAT™ Rest Assure® • SOM’s brand that encompasses the technology (sensors, docking station, software) that allows the continuous monitoring when worn and data capture • Incorporated into SOM’s existing milled COAT™ devices Herbst Advance Elite and AVANT™ •
Slide 17: Rest Assure measurements vs. CPAP
Rest Assure® measurements vs. CPAP Multiple in-mouth sensors providing objective, personalised data Sleep Position - Treatment Respiratory Usage (adherence) Efficacy Prone / Supine Interruptions Rate Surrogate AHI, Patient moving into a Remove from dock, validated by Comfortable sleeping vertical po
Slide 18: Timeline for commercial readiness
Timeline for commercial readiness Rest Assure® - overnight compliance and efficacy monitoring for COAT™ Delivered in FY22: • Finalise patent strategy • Presented at World Sleep meeting • Completion of second patient validation study • Final design completed for docking station and sensor package • S
Slide 19: Future Outlook
Future Outloo | 5°. 7am
Slide 20: Growing the sector through positioning the patient's alternative
Growing the sector through positioning the patient’s alternative Leverage One Platform and Rest Product Assure® to influence all steps Development within the patient journey and and Technology provide night time monitoring Generate clinical evidence and Clinical and healthcare economic data to Marke
Slide 21: Outlook
Outlook Advance the acceptance and adoption of technology enabled oral appliance treatment solution for OSA patients FY23 guidance Operational initiatives Strategic objectives FY2026 aspiration2 Invest EBITDA1 • Revenue growth of at • Drive medical initiative • Remain patient centric • Over 1.5 mill
Slide 22: For further information please contact:
For further information please contact: Corporate Investors Mr. Neil Verdal-Austin Mr. Craig Sainsbury CEO SomnoMed Automic Group +61 406 931 477 +61 428 550 499 Nverdal-austin@somnomed.com Craig.sainsbury@automicgroup.com.au © November 2022 SomnoMed 22